Last updated on November 2017

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin ± Pioglitazone, Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Contact Investigators or Research Sites near you

Start Over

John-Paul Suastegui

University of South Florida-Morsani College of Medicine
Tampa, FL USA